✦ LIBER ✦

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

✍ Scribed by Charles L Sawyers

Book ID: 114413190
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 66 KB
Volume: 1
Category: Article
ISSN: 1535-6108
DOI: 10.1016/s1535-6108(02)00080-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tyrosine kinase inhibitor therapy for ac

Tyrosine kinase inhibitor therapy for acute myeloid leukemia with late-appearing Philadelphia chromosome

✍ Jun Aoki; Kazuhiko Kakihana; Takeshi Kobayashi; Yuka Hirashima; Hideki Akiyama; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 225 KB

STI571, a tyrosine kinase inhibitor for

STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

✍ Michael J. Mauro; Michael E. O'Dwyer; Brian J. Druker 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 66 KB

Design, Synthesis, and Evaluation of a N

Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia

✍ Davies, Robert J.; Pierce, Albert C.; Forster, Cornelia; Grey, Ron; Xu, Jinwang; 📂 Article 📅 2011 🏛 American Chemical Society 🌐 English ⚖ 945 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Discovery of LY2457546: a multi-targeted

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

✍ Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala, James R. Henry, John 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 1007 KB

Erratum to: Discovery of LY2457546: a mu

Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

✍ Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala, James R. Henry, John 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 401 KB